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results enhance our understanding of the neural mechanisms subserving fear-pain interactions.
Introduction
Fear can illicit complex changes in neuronal processing in the descending inhibitory pain pathway. Brain regions critically involved in the descending inhibitory pain pathway include the basolateral amygdaloid complex (BLA), central nucleus of the amygdala (CeA), periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM), and neuronal activity in these regions also subserves expression of fear. A large proportion of patients suffering from persistent pain often report with co-morbid anxiety disorders 1 , and evidence suggests altered pain processing in patients suffering from anxiety disorders such as posttraumatic stress disorder 17 . Thus, studies investigating neuronal mechanisms in brain regions commonly implicated in both pain and fear may provide useful information that could be exploited for therapeutic gain.
Fear-conditioned analgesia is a phenomenon whereby animals re-exposed to a neutral context (e.g. conditioning arena) which has previously paired with an aversive stimulus (e.g. footshock) display conditioned analgesia 14, 15, 20, 24 . Information relating to context or aversion/nociception which is processed in brain regions including the thalamus and cortex converges at the level of the BLA and CeA 46 . During fear conditioning, it is postulated that the convergence of information is reinforced after each footshock. Subsequent re-exposure to the context where the aversive events occurred results in hyperexcitability and increased plasticity of neurons in the BLA 55 , and these neurons further relay the information through GABAergic intercalated cells 57 to the CeA. The medial sector of the CeA is thought to be the main source of amygdalar outputs to the PAG and hypothalamic sites responsible for fear behaviour 4,12, 31 . Indeed, neuronal projections from the CeA to the PAG 52 are strongly involved in the endogenous aversive and analgesic systems. The activation of this pathway results in both the expression of fear-related behaviour (e.g. freezing and 22-kiloHertz ultrasonic vocalisations) 10,49 and robust analgesia -as a consequence of activating the descending inhibitory pain pathway 27, 32, 37, 43 .
GABAergic neurotransmission in the BLA, CeA and PAG plays a key role in supraspinal modulation of pain 13,50 , fear 5, 9, 51, 55, 58 and fear-conditioned analgesia [19] [20] [21] . A previous microdialysis study from our laboratory reported a significant suppression of GABA levels in the BLA of fear-conditioned rats compared with non fear-conditioned controls, suggesting that reduced GABAergic signalling in the BLA may facilitate the expression of conditioned fear 51 . The present study tested the hypothesis that GABA A receptor activation in the BLA attenuates the expression of conditioned fear and fear-conditioned analgesia in rats. A pharmacological approach was adopted, employing microinjection of the GABA A receptor agonist, muscimol, bilaterally into the BLA. Furthermore, we investigated associated alterations in the expression of the immediate early gene product, c-Fos, as an index of altered neuronal activity in the CeA and PAG.
Methods

Animals
Male Lister-hooded rats (280-350 g; Charles River, Margate, Kent, UK) were used. Animals were housed 4 per cage before surgery and were maintained at a constant temperature (21 ± 
Cannulae Implantation
Stainless steel guide cannulae (Plastics One Inc., Roanoke, Virginia, USA) were stereotaxically implanted 1 mm above the right and left basolateral amygdala (AP -0.25 cm, ML ± 0.48 cm relative to bregma, DV -0.71 cm from skull surface; 48 under isoflurane anaesthesia (2-3% in O 2 ; 0.5 L/ min). The cannulae were permanently fixed to the skull using stainless-steel screws and carboxylate cement. The duration of surgery from initial anaesthesia until recovery was 50-70 minutes. A stylet made from stainless steel tubing (Plastics One Inc., Roanoke, Virginia, USA) was inserted into the guide cannula to prevent blockage by debris. 250µL of the non-steroidal anti-inflammatory agent, carprofen (0.5% s.c.) (Rimadyl, Pfizer, Kent, UK), and 250µL of the broad spectrum antibiotic, enrofloxacin (0.5% s.c.) (Baytril, Bayer Ltd., Dublin, Ireland) were administered before the surgery to manage post-operative analgesia and to prevent infection respectively. Following cannulae implantation, the rats were singly housed and administered enrofloxacin (Baytril) for a further 3 days. At least 6 days post-surgery were allowed for recovery prior to experimentation. During this period, the rats were handled and their body weight and general health monitored on a daily basis.
Drug Preparation
The GABA A receptor agonist, muscimol (Sigma-Aldrich, Dublin, Ireland), was freshly prepared on test days at a concentration of 1.0 mg/mL in sterile saline. 2.5% formalin (Sigma-Aldrich, Dublin, Ireland) solution was also freshly prepared in sterile saline on test days.
Experimental Procedures
The experimental procedure was essentially as described previously 6,15,16,51,53,54 . In brief, it consisted of two phases, conditioning and testing, occurring 24 h apart. Subjects were randomly assigned to groups and the sequence of testing was randomised. On the conditioning day, rats were placed in a Perspex fear-conditioning/ observation chamber (30 x 30 x 30 cm) and after 15 s they received the first of 10 footshocks (0.4 mA, 1 s duration;
LE85XCT Programmer and Scrambled Shock Generator, Linton Instrumentation, Norfolk, UK) spaced 60 s apart. Fifteen seconds after the last footshock, rats were returned to their home cage. Controls not receiving footshock were exposed to the chamber for an equivalent 9.5 min period.
The test phase commenced 23.5 hours later when the animals were placed under brief isoflurane anaesthesia (3% in O 2 ; 0.5 L/ min). At this time, animals received intra-BLA microinjection of either muscimol (MUSC 0.5 µg/ 0.5 µL) or sterile saline (VEH 0.5 µL) into the right and left BLA 60-90 seconds prior to formalin administration. Subjects received an intra-plantar injection of 50 µL formalin (Form 2.5% in 0.89% NaCl) or saline (Sal 0.89% NaCl) into the right hindpaw. The dose of muscimol (0.5 µg/ 0.5 µL / side) was chosen based on studies from the literature demonstrating that intra-cerebral administration of muscimol suppressed the expression of conditioned fear 34, 38 . A full description of the injection procedure has been published previously 54 . This design resulted in eight experimental groups as illustrated below Following intra-BLA injection of muscimol or vehicle, rats were returned to their home cage until 30-min post-formalin injection at which point they were returned to the same perspex observation chamber to which they had been exposed during the conditioning phase. A video camera located beneath the observation chamber was used to monitor animal behaviour, 
Behavioural Analysis
Behaviour was analysed using the Observer 5 software package (Noldus, Netherlands), which allowed for continuous event recording over each 15 min trial. A rater blind to experimental conditions assessed fear behaviour (duration of freezing while emitting 22 kHz ultrasonic vocalisation), nociceptive behaviour (composite pain score (CPS)) and general behaviours (rearing, walking and grooming), as described previously 60 . Formalin-induced oedema was assessed by measuring the change in the diameter of the right hindpaw immediately before and 2 h after formalin administration using Vernier callipers.
Histology
Following behavioural testing, rats were returned to their home cage until 2 h post-formalin administration. Rats were deeply anesthetised (5% isoflurane in O 2 ) and transcardially perfused with 100 ml of heparinised saline solution followed by 500 ml of 4% 
Results
Histological verification of injector placement
Eighty percent of the injections were placed within the borders of the right and left BLA ( 
c-Fos expression in the CeA and PAG
The effects of fear-conditioning, formalin and intra-BLA muscimol microinjection, alone or in combination, on c-Fos expression in discrete rat brain regions are presented in Table 1 . In rats receiving intra-BLA vehicle, contextually induced fear, formalin-evoked nociceptive behaviour or fear-conditioned analgesia were not associated with any alterations in c-Fos expression in the CeA or PAG. Conditioned fear was associated with significant increases in c-Fos expression throughout the PAG of muscimol-treated rats receiving intra-plantar injection of saline (Table 1; 
Discussion
The results of the present study provide evidence for an important role of GABA A receptors in the BLA in the expression of conditioned-fear and fear-conditioned analgesia.
Microinjection of the GABA A receptor agonist muscimol bilaterally into the BLA prevented the expression of contextually induced fear and fear-conditioned analgesia in rats. The former effect, but not the latter, was associated with an increase in c-Fos expression in the CeA and PAG. Together, the data suggest that activation of GABA A receptors in the BLA engages neurones along the amygdala-PAG pathway to effect a suppression of conditioned fear responding. The results further suggest differential muscimol-induced engagement of these amygdala-PAG neurones in the presence versus absence of formalin-evoked nociceptive tone.
Our data corroborate earlier findings demonstrating that microinjection of muscimol into the rat BLA complex suppresses the expression of conditioned fear 26, 34, 38 , and that the microinjection of benzodiazepines (allosteric modulators of the GABA A receptor) into the BLA reduces the suppression of pain-related behaviour by unconditioned 2,24,41 and conditioned 20,24 fear in rats. Previous in vivo microdialysis studies from our laboratory and others have shown that expression of conditioned fear is associated with a suppression of GABA release in the BLA 51,59 . Furthermore, benzodiazepine binding, mRNA and protein levels of distinct GABA A receptor subunits, GABA-synthesizing enzymes and the GABA A receptor-associated protein gephyrin are all reduced in the amygdala within hours after fear conditioning 8,22,45 . Based on these studies, we hypothesised that the reduced activation of BLA GABA A receptors that would likely result from a suppression of GABA release and a general reduction in GABAergic tone in that region may facilitate fear responding. The results of the present study, demonstrating that pharmacological activation of GABA A receptors in the BLA prevents the expression of conditioned fear and fear-conditioned analgesia, support this hypothesis. It is important to note, however, that inactivation of BLA neurons via other means, for example electrolytic or chemical lesion with non-GABA modulating agents, has also been shown to suppress the expression of contextual fear conditioning 29, 30, 33, 44 and fear-conditioned analgesia 23,25 .
To further investigate the effects of intra-BLA muscimol on neuronal activity in key Our results did reveal, however, that the suppression of conditioned fear by bilateral muscimol microinjection into the BLA was associated with a significant increase in c-Fos expression in the CeA. This finding supports previous work which has shown that the suppression of fear by the benzodiazepine diazepam, administered systemically, is also associated with increased c-Fos expression in the CeA 3 . Our data here suggest that these c- 
